Planet Labs PBC PL · NYSE
$13.59 +0.22% (+$0.03)
Summary
31 / 100 · Bulios Score
What speaks for it
- Revenue grew by 17% a year over the last 3 years.
- Analysts expect revenue to grow by 42% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 17% a year. For the next fiscal year analysts expect revenue to grow by 42%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $359.9M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 21.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 10
- Sell 0
Today's price within the analysts' price targets
The average target of $34.71 is 155% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
- North America 43%
- EMEA 34%
- Asia Pacific And Japan 19%
- Latin America 4.0%
Reportable Segment brings in 100% of revenue.
Segments in detail